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Histone acetylation plays important roles in gene
regulation, DNA replication, and the response to
DNA damage, and it is frequently deregulated in
tumors. We postulated that tumor cell histone acety-
lation levels are determined in part by changes in
acetyl coenzyme A (acetyl-CoA) availability mediated
by oncogenic metabolic reprogramming. Here, we
demonstrate that acetyl-CoA isdynamically regulated
by glucose availability in cancer cells and that the
ratio of acetyl-CoA:coenzyme A within the nucleus
modulates global histone acetylation levels. In vivo,
expression of oncogenic Kras or Akt stimulates
histone acetylation changes that precede tumor
development. Furthermore, we show that Akt’s ef-
fects on histone acetylation are mediated through
the metabolic enzyme ATP-citrate lyase and that
pAkt(Ser473) levels correlate significantly with his-
tone acetylation marks in human gliomas and
prostate tumors. Thedata implicateacetyl-CoAmeta-
bolism as a key determinant of histone acetylation
levels in cancer cells.
INTRODUCTION
Rewiring of cellular metabolism in cancer cells is crucial for
increased macromolecular biosynthesis, growth, and prolifera-
tion, and metabolic deregulation is now considered a hallmark
feature of cancer cells (Hanahan and Weinberg, 2011; Ward306 Cell Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier Incand Thompson, 2012). In addition to directly supporting ener-
getics and biosynthesis, a growing body of evidence suggests
that metabolic enzymes may also promote tumorigenesis
through functions that are not overtly metabolic. For example,
the M2 isoform of pyruvate kinase, a glycolytic enzyme, has
been reported to enter the nucleus and serve as transcrip-
tional coregulator (Luo and Semenza, 2012). ATP-citrate lyase
(ACLY), a lipogenic enzyme, is also present in the nucleus and
plays a crucial role in regulating nuclear acetylation events,
including histone acetylation (Wellen et al., 2009).
Metabolic changes in cancer cells are typically mediated
by activation of oncogenes and/or loss of tumor suppressors.
Hence, mutations that drive tumorigenesis also cause metabolic
alterations. In addition to genetic mutations, epigenetic alter-
ations play a key role in enabling malignant transformation and
tumor growth (Azad et al., 2013; Shen and Laird, 2013), although
mechanisms underlying epigenetic alterations in cancer are not
fully clear. Notably, many chromatin-modifying enzymes depend
on metabolic intermediates as cofactors or substrates, and
certain chromatinmodifications have been shown to be sensitive
to the cellular metabolic state (reviewed in Kaelin and McKnight,
2013; Katada et al., 2012; Lu and Thompson, 2012; Yun et al.,
2012). Links between cancer cell metabolism and DNA and his-
tone methylation have been recently identified in tumors with
specific mutations, such as those in isocitrate dehydrogenase
(IDH1 and IDH2). Mutant IDH enzymes exhibit altered enzyme
activity favoring conversion of a-ketoglutarate (aKG) into (R)-
2-hydroxyglutarate, a metabolite that inhibits the activity of
aKG-dependent JmjC-domain histone demethylases and TET
enzymes, resulting in hypermethylation of DNA and histones
(reviewed in Losman and Kaelin, 2013; Ward and Thompson,
2012). Succinate dehydrogenase (SDH) mutations and nicotin-
amide N-methyltransferase (NNMT) overexpression also result.
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Letouze´ et al., 2013; Ulanovskaya et al., 2013; Xiao et al.,
2012). In these specific cases, the epigenetic alterations are a
direct result of altered activity of a particular metabolic enzyme.
However, it is not knownwhethermetabolismmightmore univer-
sally contribute to tumor epigenetic deregulation.
Histoneacetylation isadynamicchromatinmark,with important
roles in gene regulation, DNAdamage repair, andDNA replication.
Global histoneacetylationhasalsobeen implicated incontributing
to pH balance and postulated to serve as a depot for acetate that
could be mobilized as an energy source (Martinez-Pastor et al.,
2013; McBrian et al., 2013). The metabolite acetyl coenzyme A
(acetyl-CoA) is the required donor substrate used by lysine ace-
tyltransferase (KAT) enzymes. In cells cultured under standard
conditions, glucose-derived carbon supplies the majority of
acetyl-CoA used for histone acetylation, although glutamine and
acetate also contribute (Evertts et al., 2013). In some conditions,
fatty acid breakdown can also contribute to nuclear acetyl-CoA
andhistoneacetylation (Donohoeetal., 2012). Acetyl-CoA iscom-
partmentalized into mitochondrial and nuclear-cytoplasmic pools
(Takahashi et al., 2006). Productionof nuclear-cytoplasmicacetyl-
CoA from glucose, glutamine, or fatty acids depends on export
of citrate from the mitochondria, where it is cleaved by ACLY to
generate acetyl-CoA and oxaloacetate. Acetate also supplies
nuclear-cytoplasmic acetyl-CoA through acetyl-CoA synthetase
(ACECS1/ACSS2). Together, ACLY and ACECS1 are the primary
enzymatic sources of acetyl-CoA outside of the mitochondria.
Several studies have demonstrated that histone acetylation levels
are highly sensitive to the availability of acetyl-CoA, in cell types
from yeast to human (Cai et al., 2011; Donohoe et al., 2012; Friis
et al., 2009; Takahashi et al., 2006; Wellen et al., 2009).
Given that production and utilization of metabolites is dramat-
ically altered in cancer cells, and that histone acetylation is
responsive to acetyl-CoA availability, we postulated that meta-
bolic reprogramming in tumor cells might alter acetyl-CoA and
histone acetylation levels in tumors. In this study, we provide
evidence that metabolic reprogramming orchestrated by onco-
genic activation of Akt drives changes in acetyl-CoA production
and histone acetylation that are reflected in total histone acety-
lation levels in tumors. This study demonstrates that metabolic
reprogramming mediated by oncogenic activation of a signal
transduction pathway plays a major role in regulation of the
cancer cell epigenome.
RESULTS
Histone Acetylation Is Variably Sensitive to Glucose in
Cancer Cells
We previously showed that ACLY plays a key role in determining
global histone acetylation levels in cancer cells. Histone acetyla-
tion is markedly reduced upon silencing of ACLY and can be
restored by supplementing cells with the alternate acetyl-CoA
source acetate, indicating that the ability of cells to produce
acetyl-CoA can limit histone acetylation (Wellen et al., 2009).
To determine whether glucose availability regulates histone
acetylation levels in cancer cells, we examined a panel of cancer
cell lines, including glioblastoma, prostate cancer, and breast
cancer cell lines. Histone acetylation was sensitive to glucose
availability in each of the cell lines examined, to varying degreesCel(Figures 1A and S1A, available online). As we have previously
shown in other cell types (Wellen et al., 2009), silencing of
ACLY inhibited glucose-dependent histone acetylation in
LN229 cells (Figure S1B).
In LN229 glioblastoma cells, proliferation slowed when
cultured in 1 mM glucose, but between 2 and 25 mM glucose
doubling time was equal, indicating that histone acetylation pat-
terns are regulated by glucose independently of cell proliferation
(Figure S1C). Cells remained viable in all conditions (Figure S1C).
As glucose was progressively limited, glutamine consumption
increased (Figure S1C). Although glutamine can be used to
supply nuclear-cytoplasmic acetyl-CoA, LN229 cells failed to
sustain high histone acetylation levels in low glucose despite
increased consumption of glutamine (Figure 1A).
We next sought to define which histone lysines are most
sensitive to glucose availability. LN229 cells were incubated for
24 hr in 1 mM or 10 mM glucose, and histone modifications
were analyzed by mass spectrometry. Higher acetylation in
10 mM compared to 1 mM glucose was observed at all H2A,
H3, and H4 tail lysines analyzed (Figure S1D and Table S1). To
confirm that this is due to reduced glucose carbon incorporation
into acetylated histones, this analysis was repeated in 1 mM or
10 mM [U-13C6]glucose. After 24 hr, enrichment was reduced
in low glucose for all lysines analyzed (Table S2). However, the
effects of glucose limitation became more pronounced as
more lysines were acetylated in cis. For example, the histone
H4 tail can be acetylated at lysines 5, 8, 12, and 16. In 1 mM
[U-13C6]glucose, significantly more tetra-acetylated histone H4
(AcH4) tails were enriched at 0 or 1 acetyl group, while in
10 mM, 3 or 4 acetyl groups were more frequently enriched (Fig-
ure S1E). Thus, these data indicate that (1) on all tail lysines
examined, acetylation is sensitive to glucose availability, and
(2) glucose limitation has a greater impact on histone tails with
multiple lysines acetylated in cis.
Supplementation of acetate restored histone acetylation
levels in low glucose conditions (Figure 1B). Correspondingly,
acetyl-CoA levels were reduced in low glucose conditions and
significantly rescued by addition of acetate (Figure 1C). To deter-
mine whether specific gene sets correlated with these effects on
histone acetylation, we performed RNA sequencing to identify
acetyl-CoA-regulated genes (genes suppressed or induced by
low glucose and reversed by acetate). Approximately 10% of
glucose-regulated genes were also significantly regulated by
acetate (Figure 1D). Clustering analysis revealed that acetate
regulated most genes in the same direction as glucose, suggest-
ing that acetyl-CoA is a key mediator of glucose-dependent
gene expression (Figure 1E and Table S3). Expression was
confirmed for select acetyl-CoA-regulated genes by quantitative
PCR (qPCR) (Figure S2A), and chromatin immunoprecipitation
(ChIP) analyses at these genes showed that promoter histone
acetylation correlated with expression (Figure S2B). Analysis
of curated pathways revealed enrichment for genes involved
in cell cycle and DNA replication among acetyl-CoA-induced
genes, suggesting that acetyl-CoA stimulates a pro-proliferative
gene expression profile (Figure 1F). Analogously, prior studies in
yeast showed that acetyl-CoA promotes cell growth and division
by promoting expression of genes involved in these processes
(Cai et al., 2011; Shi and Tu, 2013). Although acetate supplemen-
tation was not sufficient to restore normal doubling time inl Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier Inc. 307
(legend on next page)
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that additional glucose-derived components might be required.
Indeed, supplementation of acetate together with nucleosides
(synthesis of which requires ribose generated in the pentose
phosphate pathway) rescued doubling time, while neither
component alone did so (Figure 1G). These data suggest that
acetyl-CoA facilitates expression of proliferation-related genes
as part of an integrated growth response.
Acetyl-CoA and Coenzyme A Are Key Determinants of
Histone Acetylation in Cancer Cells
If acetyl-CoA serves as a signal of nutrient sufficiency to promote
growth and proliferation, cells must have mechanisms to detect
changes in acetyl-CoA abundance. Work in yeast has shown
that Gcn5 is crucial for mediating histone acetylation in response
to acetyl-CoA availability (Cai et al., 2011; Friis et al., 2009). In
yeast, acetyl-CoA concentrations oscillate within a range that
could plausibly regulate yeast Gcn5, which has a KD of 8.5 mM
(Cai et al., 2011). However, human GCN5 binds acetyl-CoA
much more tightly (KD of 0.56 mM) (Langer et al., 2002). This sug-
gests either that levels of acetyl-CoA are lower in human cells
than in yeast or that the absolute concentration of acetyl-CoA
is not the key regulatory factor for overall histone acetylation
levels in human cells. Notably, many lysine acetyltransferases
(KATs) including GCN5 are inhibited by the product CoA and
bind acetyl-CoA and CoA with similar affinities. Hence, it has
been postulated that the ratios of these metabolites might be
the critical determinant for overall histone acetylation levels
(Albaugh et al., 2011).
We therefore measured absolute acetyl-CoA and CoASH
(reduced CoA) concentrations, normalized to cell volume, in
LN229 cells cultured in 1 or 10 mM glucose. Acetyl-CoA was
measured at 6–13 mM in high glucose conditions and fell to
2–3 mM in low glucose. CoASH tended to rise in low glucose,
and the ratio of acetyl-CoA:CoASH was found to be 1.5–2
throughout the time course in high glucose conditions and to
fall below 1 under low glucose (Figure 2A). We also examined
acetyl-CoA and CoASH levels in a second cell line, IL-3-depen-
dent hematopoietic cells, since the volume of these cells under
standard conditions and during nutrient and growth factor with-
drawal has been extensively characterized (Lum et al., 2005;
Wellen et al., 2010). A similar range of acetyl-CoA concentrations
(3–12 mM) were measured in these cells as in LN229 cells, and
both acetyl-CoA and acetyl-CoA:CoASH were significantly
reduced when cells were deprived of either glucose or growth
factor (Figure 2B). The range of acetyl-CoA concentrations
observed in each of these cell lines is comparable to that
reported over the yeast metabolic cycle (Cai et al., 2011).
To specifically test whether histone acetylation levels respond
to both acetyl-CoA and CoA levels, nuclei were isolated fromFigure 1. Glucose Availability Regulates Histone Acetylation in Severa
(A) Acetylation of acid-extracted histones from cells cultured under indicated gluco
(B) Acetylation of acid-extracted histones from LN229 cells treated with 1 or 10
(C) Relative levels of acetyl-CoA in LN229 cells after 24 hr of indicated treatmen
(D) Venn diagram of genes regulated by glucose and/or acetate in LN229 cells, w
(E) Heatmap of 881 genes represented in the overlap from the Venn diagram. Se
(F) DAVID functional annotation of pathways regulated by acetyl-CoA, using the
(G) Doubling time for LN229 cells treated as indicated for 24 hr; mean ± SEM of
CelLN229 cells and incubated with defined concentrations of
acetyl-CoA and CoASH, which can freely enter the nucleus
through the nuclear pore complex. We observed that in the pres-
ence of high acetyl-CoA, addition of CoASH suppressed histone
acetylation in a dose-dependent manner (Figure 2C). Together,
these data indicate that levels of both acetyl-CoA and CoA in
the nucleus can impact histone acetylation levels. Moreover,
the ratio of acetyl-CoA:CoASH is glucose sensitive and tracks
with total acetyl-CoA.
Expression of KrasG12D in the Mouse Pancreas
Promotes Increased Histone Acetylation Prior to Tumor
Development
Since histone acetylation is sensitive to metabolic state and
metabolism is altered in cancer cells, we next asked whether
oncogene activation could drive changes in histone acetylation
in vivo. Oncogenic KRASmutations are found in the vast major-
ity of human pancreatic adenocarcinoma (PDA) cases, and
recent studies have demonstrated that mutant Kras in pancre-
atic cancer cells drives extensive metabolic rewiring (Son
et al., 2013; Ying et al., 2012). We observed that in the pancreas
of healthy wild-type (WT) mice, acinar cells exhibited very low
levels of AcH3 and AcH4, as detected by immunohistochem-
istry (IHC), although ductal cells were strongly positive for
these marks (Figure 3A). In contrast, in mice expressing onco-
genic Kras (LSL-KrasG12D; p53L/+; Pdx1-Cre [KPC] mice), areas
of acinar-to-ductal metaplasia (ADM), precancerous pancreatic
intraepithelial neoplasia (PanIN), and PDA exhibited high levels
of AcH3 and AcH4 (Figure 3A and 3B). PDA may arise from
acinar cells (Morris et al., 2010), and strikingly, elevated AcH4
was observed in acinar cells even prior to increases in prolifer-
ation, as assessed by Ki67 immunostaining (Figure 3C) or the
appearance of any histological abnormalities (Figures 3A and
S3). Thus, histone acetylation levels are elevated upon KrasG12D
expression in mouse pancreas early in the process of tumor
development.
We next interrogated signaling pathways downstream of Kras
to identify those responsible for elevating histone acetylation in
primary murine PanIN cells. Reductions in histone acetylation
were observed with each of the inhibitors that we tested (Fig-
ure 4A). Phosphatidylinositol 3-kinase (PI3K) and Akt inhibition
also significantly reduced glucose uptake and lactate consump-
tion and suppressed Acly phosphorylation (Figures 4A and 4B).
Phosphorylation at Ser455 has been shown to increase ACLY’s
activity (Potapova et al., 2000). On the other hand, the level of
AceCS1, which produces nuclear-cytoplasmic acetyl-CoA
from acetate, was somewhat suppressed by PI3K, but not by
Akt, inhibition in these cells (Figure 4A). Acetyl-CoA and acetyl-
CoA:CoASH levels were potently suppressed upon Akt inhibition
(Figure 4C), and histone acetylation levels in Akt inhibitor-treatedl Cancer Cell Lines
se conditions for 24 hr. Total histones were stained by Coomassie or Ponceau.
mM glucose, with or without 5 mM NaOAc for 24 hr.
t; mean ± SEM of triplicates (*p < 0.05; **p < 0.005).
ith the overlap representing genes designated as acetyl-CoA regulated.
e Table S3 for associated gene list and cluster ID.
gene list identified from the indicated clusters on the heatmap.
triplicates (*p < 0.05; **p < 0.005).
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Figure 2. Acetyl-CoA:CoASH Ratio Is a Determinant of Histone Acetylation in Cancer Cells
(A) Molar concentrations of acetyl-CoA, CoASH, and ratio of acetyl-CoA:CoASH over 24 hr in LN229 cells; mean ± SEM of triplicates. Result is representative of
three independent experiments.
(B) Interleukin-3 (IL-3)-dependentBax/Bak/ cells were cultured for 48 hr with or without glucose andwith or without IL-3 as indicated. Acetyl-CoA andCoASH
were measured and normalized to cell volume; mean ± SD of triplicates. Significance as compared to Glc+IL-3+ samples (*p < 0.05, **p < 0.005, ***p < 0.0005).
(C) Representative western blot of acetylated histones upon incubation of isolated nuclei with varying concentrations of acetyl-CoA and CoASH. Total histones
were stained by Ponceau. Data were quantified from four independent experiments with 25:0 value set to 1; mean ± SEM. Repeated-measures one-way ANOVA
with posttest for linear trend was performed for 25:10–25:100 values. Posttest for linear trend significance for AcH4:H4, ***p < 0.0001; for AcH3:H3, **p = 0.0034.
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ure 4D). Suppression of histone acetylation by Akt inhibition
was comparable to that observed upon either glucose limitation
or Acly silencing, both of which were also rescued by acetate
(Figure 4D). In primary murine PDA cells, we similarly observed
suppression of histone acetylation and glucose uptake by PI3K
or Akt inhibition, as well as acetate rescue of histone acetylation
in Akt inhibitor- or low glucose-treated cells (Figure S4B–S4D).
These data indicate that in premalignant and cancerous cells ex-310 Cell Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier Incpressing oncogenic Kras, histone acetylation is regulated in part
by Akt-dependent regulation of acetyl-CoA metabolism.
Akt Activation Sustains Histone Acetylation in Nutrient-
Limited Conditions
To probe further into the mechanism by which Akt regulates
histone acetylation, we examined the effects of constitutive Akt
activation in cancer cells by comparing parental LN229 cells
with LN229 cells in which a constitutively active form of Akt,.
Figure 3. Oncogenic Kras Increases Histone Acetylation In Vivo
(A–C) Pancreata from mice expressing Kras-G12D (KPCY, previously described; Rhim et al., 2012) were harvested at either 6 weeks (KPCY-Normal Area),
8 weeks (KPCY-PanIN), orR10 weeks (KPCY-PDA) of age, along with pancreata from control (Kras WT) mice (nR 3 for each group). Immunohistochemistry
against AcH4 (A), AcH3 (B), or Ki67 (C) was performed on paraffin-embedded tissue sections, and nuclei were counterstained with hematoxylin. Representative
images are shown, with magnification of areas of interest. Scale bar, 50 mm. See Figure S3 for quantification of AcH4 in acinar cells in Kras WT and KPCY mice.
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Metabolic Control of Tumor Histone Acetylationmyristoylated Akt (myrAkt), was stably expressed. LN229-
myrAkt cells have been shown to consume more glucose
but maintain a proliferation rate similar to that of parental
cells (Elstrom et al., 2004). Levels of histone acetylation in high
glucose conditions were not markedly different between the
two cell lines. However, when cultured in low glucose, LN229-
myrAkt cells sustained a level of histone acetylation significantly
higher than that of parental cells (Figure 5A). Similar results were
also obtained in SF188 and SF188-myrAkt cells (Figure S5A).
Time course analysis indicated that myrAkt expression extended
the time frame over which cells could maintain histone acetyla-
tion levels in low glucose (Figure S5B).
Glucose deprivation results in depletion of ACLY’s substrate
citrate in LN229 cells (Figure S6A). In myrAkt-expressing cells,Celcitrate levels were lower than in the parental cells, even in high
glucose conditions, and loss of citrate was accelerated upon
glucose deprivation (Figure S6A). In vitro studies of ACLY enzy-
matic activity have demonstrated that phosphorylation at Ser455
increases the enzymatic activity of ACLY, resulting in a 6-fold in-
crease in V(max) (Potapova et al., 2000). Hence, increased phos-
phorylation of ACLY by Akt could potentially enable sustained
acetyl-CoA production and thereby histone acetylation even if
availability of the ACLY substrate citrate is reduced. To test
whether ACLY phosphorylation is sufficient to sustain high levels
of histone acetylation in low glucose, we expressed WT Acly
and Acly Ser455 phosphomimetic (S455D) and phosphomutant
(S455A) proteins in LN229 cells. Expression of Acly-S455D
enabled high levels of histone acetylation to be sustained inl Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier Inc. 311
Figure 4. Oncogenic Kras Enhances His-
tone Acetylation In Vitro in an Akt- and
Acly-Dependent Manner
(A) Mouse pancreatic primary cells derived from
KPCY mouse PanIN lesions were treated with the
indicated inhibitors for 24 hr. Acetylation of his-
tones and phosphorylation of signaling proteins
were assessed by western blot in acid extracts
and RIPA lysates, respectively. Ponceau staining
is shown as loading control for histones.
(B) Glucose consumption and lactate production
were measured in PanIN-derived primary mouse
cells treated as in (A); mean ± SD of triplicates
(*p < 0.05).
(C) Acetyl-CoA and CoASH levels were measured
in PanIN cells, with or without Akt inhibitor; mean ±
SD of triplicates (***p < 0.001).
(D) PanIN-derived primary cells were transduced
with control (shCtrl) or Acly-targeting (shAcly)
short hairpin RNA. Cells were cultivated under
indicated glucose concentrations, with or without
Akt inhibitor and with or without 5 mM acetate for
24 hr. Histones were acid extracted and analyzed
by western blot. Ponceau staining is shown as
loading control for histones.
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(Figure 5B). A trend toward higher histone acetylation in low
glucose was also noted with expression of WT Acly. These re-
sults suggest that ACLY is a key downstream effector of Akt in
promoting histone acetylation, particularly when nutrients are
limited.
This result raised the question of where cells obtain the carbon
for histone acetylation in cells with constitutive Akt/ACLY activa-
tion but limited glucose. Recent studies have shown that under
certain conditions such as hypoxia, glutamine can be reductively
carboxylated to generate citrate and supply lipogenic acetyl-CoA
and that depletion of citrate or an elevateda-ketoglutarate:citrate
ratio is necessary for this effect (Fendt et al., 2013; Gameiro et al.,
2013). We hypothesized that citrate depletion observed with
myrAkt expressionmight stimulate glutamine reductive carboxyl-
ation. However, analysis of citrate isotopologues following expo-
sure to [13C5
15N2]glutamine revealed that glutamine continues to312 Cell Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier Inc.be oxidized in myrAkt-expressing cells
and that little to no reductive carboxyla-
tion occurred in either high or low glucose
conditions (Figure S6B). On the other
hand, acetyl-CoA, though significantly
depleted in control orWTAcly-expressing
cells in low glucose, retained a com-
parable percent of enrichment from
glucose (m+2 acetyl-CoA) when cultured
in either 1 mM or 10 mM [U-13C6]glucose
(Figure 5C). Moreover, in Acly-S455D-
expressing cells, both total and m+2
acetyl-CoA resisted depletion in low
glucose (Figure 5C), suggesting that
even when glucose is limited, it re-
mains a major source of acetyl-CoA in
this context.Hence, the data indicate that Akt promotes acetyl-CoA pro-
duction and histone acetylation through combined effects
on (1) promoting the uptake and metabolism of glucose and (2)
promoting phosphorylation and activation of ACLY to facilitate
continued acetyl-CoA production even when its substrate citrate
is limited.
Akt Activation Acutely Promotes Histone Acetylation
In Vivo
To directly test whether acute activation of Akt regulates histone
acetylation in vivo, we exploited a doxycycline-inducible mouse
model of breast cancer in which myrAkt is activated in mammary
epithelial cells upon administration of doxycycline to mice
through the drinking water (Gunther et al., 2002). pAkt and pAcly
levels increased with myrAkt expression, as expected (Fig-
ure 5D). In control animals, relatively weak staining for AcH4
was detected in ductal epithelial cells. Remarkably, however,
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tion were detected within 96 hr of doxycycline administration
(Figure 5D). On the other hand, another activating mark,
H3K4me1, was not obviously regulated, suggesting that histone
acetylation—not histone marks in general—may be specifically
impacted by Akt activation. Hence, acute activation of Akt in vivo
increases global histone acetylation levels.
These data indicate that activation of Akt acutely promotes
histone acetylation. We next investigated whether Akt activa-
tion is associated with histone acetylation in established human
tumors.
Histone Acetylation Levels Correlate with pAKT in
Human Glioma
The PI3K/Akt pathway is frequently activated in glioblastoma
multiform (GBM), due to epidermal growth factor receptor
(EGFR) or phosphatase and tensin homolog (PTEN) mutations
(Lino and Merlo, 2011). We examined a diverse panel of human
gliomas to determine whether AcH4 is associated with pAKT
levels. A total of 56 samples on a tumor tissue microarray (TMA)
were analyzed for pAKT and AcH4 (Figure 6A). Each tumor sam-
ple was scored in a blinded manner by a neuropathologist and
given a combined score for the percentage of positive cells and
intensity of staining (H score) for both pAKT and AcH4. A statisti-
cally significant positive correlation was found between pAKT
and AcH4, indicating that AKT activation is associated with
increased histone acetylation in human tumors (Figure 6B).
pAKT levels tended to increase with tumor grade, particularly in
astrocytomas, although no significant relationship was observed
between tumor grade and AcH4 (Figure 6C). The relationship be-
tween pAKT andAcH4 is therefore not secondary to effects of tu-
mor grade. IDH1 (and to a lesser extent IDH2) mutations occur
frequently in gliomas and alter both cell metabolism and epige-
netics (Losman and Kaelin, 2013). Of particular relevance, IDH
mutations cause hypermethylation of histones (Lu et al., 2012),
suggesting the possibility that histone acetylation might be
altered secondarily to methylation effects in IDHmutant tumors.
H3K9me3was previously shown to be elevated in IDHmutant tu-
mors in this patient set (Venneti et al., 2013a), and we found no
significant relationship between H3K9me3 and pAKT levels
(data not shown). Moreover, AcH4 levels were not different be-
tween IDHWT and IDHmutant tumors (Figure 6D).
Histone Acetylation Levels Correlate with pAKT in
Human Prostate Cancer
In human prostate tumors, significant correlations have been re-
ported between levels of histone acetylation marks with tumor
grade (H3K18ac and H4K12ac) as well as with the risk of tumor
recurrence (H3K18ac, H3K9ac, and H4K12ac) (Bianco-Miotto
et al., 2010; Seligson et al., 2005). The PI3K/Akt pathway is
frequently activated in prostate cancer due to PTEN loss or other
mutations, and inhibition of Akt in the PTEN null prostate cancer
cell lines PC-3 and C4-2 reduced overall levels of histone acety-
lation (Figure S7A). We investigated levels of three histone
acetylation marks (H3K18ac, H3K9ac, and H4K12ac) and their
association with pAKT(Ser473) in a panel of human prostate
tumors (Figure 7A). The cohort consisted of patients with either
metastatic or localized disease, with primary tumor grades
ranging from 3 to 5 on the Gleason scale. Tumors were scoredCelfor both the percentage of positive cells and the intensity of stain-
ing. A striking positive correlation was observed between pAKT
and each of the histone acetylation marks (Figure 7B). Levels of
each histone acetylation mark were also strongly correlated with
one another in tumors (Figure S7B). Percentages of nuclei posi-
tive for H3K18ac were similar between patients with metastatic
as compared to localized disease, while H3K9ac and particularly
H4K12ac scored positive in a higher percentage of nuclei in pa-
tients with metastatic disease (Figure S7C). H4K12ac was also
higher in Gleason 4 and 5 tumors than in Gleason 3 samples (Fig-
ure S7D). Together, the data from human prostate cancer and
glioma suggest that AKT activation is a major determinant of his-
tone acetylation levels in tumors.
Histone Acetylation as a Predictive Biomarker for
Therapeutic Failure
For ten of the prostate cancer patients with localized disease,
biochemical failure (PSA recurrence) data were available. Strik-
ingly, levels of histone acetylation were highly predictive of which
patients would later exhibit biochemical failure. The five patients
with the lowest levels of H4K12ac, H3K18ac, and H3K9ac devel-
oped biochemical failure, whereas the five with the highest levels
of these marks did not (Figure 7C). These findings agree with
those of Seligson et al. (2005), showing that low levels of histone
modifications such as H3K18ac are associated with a poor prog-
nosis in prostate cancer. Within these ten samples, the relation-
ship between pAKT and each histone acetylation mark held
(Figure S7E), although pAKT levels did not predict biochemical
failure in these ten samples (Figure 7C). Hence, histone acetyla-
tion levelsmight be a valuable biomarker to predict tumor relapse.
DISCUSSION
We report that oncogenic Akt activation is a key determinant
of global histone acetylation levels in cancer cells. We provide
evidence that this occurs through Akt-dependent metabolic re-
programming to promote high acetyl-CoA production. Akt en-
sures continuous acetyl-CoA production even during nutrient
limitation by promoting the phosphorylation and activation of
ACLY. This report implicates metabolic reprogramming medi-
ated by oncogenic activation of a signal transduction pathway
as a major factor underlying tumor epigenomic regulation.
Elucidating the regulation of tumor histone acetylation levels is
important clinically, and the mechanisms that control tumor his-
tone acetylation are currently poorly understood. Our data sug-
gest that metabolic effects contribute to determining histone
acetylation levels in tumors. Other relevant factors in addition
to acetyl-CoA metabolism include levels of KATs and histone
deacetylases (HDACs), as well as tumor pH. The significance
of global histone acetylation levels is not yet fully clear. Several
studies have examined the relationship between histone acetyla-
tion levels and tumor recurrence and patient survival in various
cancer types (reviewed in Chervona andCosta, 2012; Kurdistani,
2007). Significant correlations have been shown in several
studies, although high histone acetylation has been associated
with both better and worse prognoses, likely reflecting differ-
ences in types of cancer, tumor grade, therapeutic approaches,
and sample stratification. Our data suggest that low levels of his-
tone acetylation may predict poor patient outcome in prostatel Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier Inc. 313
(legend on next page)
Cell Metabolism
Metabolic Control of Tumor Histone Acetylation
314 Cell Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier Inc.
Figure 6. pAKT Correlates with Histone
Acetylation in Human Glioma
(A) Representative images (203) of pAKT and
AcH4 in a grade IV GBM and a grade II oligoden-
droglioma.
(B) pAKT expression showed a significant corre-
lation with AcH4 levels in 56 human glioma sam-
ples (r = 0.4721, p = 0.0002).
(C) pAKT and AcH4 in astrocytic tumors (grade IV
astrocytomas = GBM) and oligodendrogliomas;
mean ± SD.
(D) pAKT and AcH4 levels in 10 IDHmutant and 21
IDH WT gliomas; mean ± SD.
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Metabolic Control of Tumor Histone Acetylationcancer, similar to the findings of Seligson et al. (2005). Further
study is needed to understand how global histone acetylation
levels impact tumor growth and progression as well as treatment
responses.
It will be crucial to further investigate the functions ofmetabolic
control of acetylation, as well as the role of ACLY levels and
phosphorylation, in regulating gene expression and promoting
tumorigenesis. ACLY silencing is known to inhibit cancer cell pro-
liferation and suppress tumor growth (Bauer et al., 2005; Hatzi-
vassiliou et al., 2005; Migita et al., 2008). While suppression of
de novo lipogenesis in the absence of ACLY is certainly a key
component of this antitumor effect, a growing body of literature
indicates that acetylation also plays a crucial role in promoting
anabolic metabolism and growth. Acetyl-CoA has been shown
to promote growth and proliferation in yeast, through histone
acetylation at genes involved in these processes (Cai et al.,
2011; Shi and Tu, 2013). Moreover, acetyl-CoA and acetylation
regulate many metabolic enzymes (Guan and Xiong, 2011), and
a role for acetyl-CoA in suppressing autophagy has also recentlyFigure 5. Akt Activation Allows Sustained Histone Acetylation in Glucose-Limited Conditions
(A) Western blot analysis of proteins and histones from LN229 and LN229-myrAkt cells. Quantitation represen
samples set to 1; mean ± SEM (*p% 0.05).
(B) Western blot analysis of histone acid extracts from LN229 cells stably expressing vector (EV), WT Acly, Ac
or 10 mM glucose for 24 hr before lysis. Quantitation represents the ratio of acetylated to total histones in fou
mean ± SEM (*p < 0.05).
(C) Relative acetyl-CoA concentrations and percent enrichment after treatment in 1 mM or 10 mM [U-13C6]g
acetyl-CoA levels as well as m+2 acetyl-CoA (enriched from glucose) were significantly suppressed (p < 0.05
WT-Acly cells, but not Acly-S455D cells.
(D) Control (MTB) and transgenic (MTB-tAkt) mice were administered doxycyclin for 96 hr (n R 5 for each
paraffin-embedded mammary tissue sections. Representative images are shown, along with magnification
Cell Metabolism 20, 306–31been uncovered (Eisenberg et al., 2014;
Marin˜o et al., 2014). We show here that
many proliferation-related genes are
acetyl-CoA regulated in glioblastoma
cells, correlatingwith overall histone acet-
ylation levels as well as histone acetyla-
tion at these genes. Thus, our study
adds to a growing body of literature that
implicates acetyl-CoA in providing pro-
growth cues to the cell.
We have focused this study on the role
of the PI3K/Akt pathway in regulation of
acetyl-CoA production and histone acet-
ylation. Many oncogenes and tumor sup-pressors are now recognized to regulate cellular metabolism.
Microenvironmental conditions such as hypoxia also potently
reprogram cellular metabolism. Moreover, in addition to acetyl-
CoA, metabolites such as UDP-GlcNAc, S-adenosylmethionine
(SAM), and a-ketoglutarate are also required by chromatin-
modifying enzymes and could potentially impact the epigenome
if their levels are altered in tumors (Lu and Thompson, 2012). It is
therefore conceivable that alteredmetabolite utilization substan-
tially alters chromatin in many or most cancer cells.
Intense effort is currently aimed at targeting both cancer cell
metabolism and cancer epigenetics (Dawson and Kouzarides,
2012; Vander Heiden, 2011). If metabolism is indeed a critical
mediator of cancer cell epigenetic deregulation, it is possible
that epigenetic alterations could be reversed through therapeu-
tics directed at metabolic targets. Improved understanding
of metabolic regulation of the epigenome could point toward
contexts in which existing epigenetic therapies, such as HDAC
inhibitors, would be most effective or could open doors to devel-
opment of more specific therapeutics targeting the intersectionts five independent experiments with LN229 4 mM
ly-S455A, or Acly-S455D. Cells were treated with 1
r independent experiments with EV 10 mM set to 1;
lucose for 20 hr; mean ± SEM of triplicates. Total
) in 1 mM as compared to 10 mM glucose in EV and
group). Immunohistochemistry was performed on
of areas of interest. Scale bar, 50 mm.
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Figure 7. pAKT Correlates with Histone Acetylation Levels in Human Prostate Cancer
(A) Representative images of H3K18ac, H3K9ac, H4K12ac, and pAKT expression detected by immunohistochemistry in Gleason grade 3–5, metastatic (n = 25),
and nonmetastatic (n = 24) prostate cancer tumors.
(B) H scores were determined, and correlations between marks were determined. pAKT expression showed a significant correlation with H3K18ac levels
(r = 0.7452, p < 0.0001), H3K9ac (r = 0.6283, p < 0.0001), and H4K12ac (r = 0.5276, p < 0.0001).
(C) Box plot showing H scores for H4K12ac, H3K18ac, H3K9ac, and pAKT in prostate cancer tumors in patients that did (Yes) or did not (No) develop PSA failure
(**p < 0.005, *p < 0.05).
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pathway is a key determinant of histone acetylation levels in
tumors represents an important step forward in understanding
the extent to which oncogenic metabolic reprogramming could
control the epigenome.316 Cell Metabolism 20, 306–319, August 5, 2014 ª2014 Elsevier IncEXPERIMENTAL PROCEDURES
Reagents and Cell Lines
LN229-myrAkt cells have been previously described (Elstrom et al., 2004).
LN229-myrAkt andSF188-myrAkt cells were a gift of C.B. Thompson,MSKCC.
LN229-Acly, LN229-S455A, and LN229-S455D and empty vector stable.
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Metabolic Control of Tumor Histone Acetylationcell lines were generated by transfecting cells with pEF6, pEF6-Acly(WT),
pEF6-Acly(S455A), or pEF6-Acly(S455D) constructs and selecting. See the
Supplemental Experimental Procedures for specific culture conditions and
information on inhibitors and antibodies used.
YSI Metabolite and Doubling Time Measurements
Glucose and glutamine consumption and lactate production were measured
using a YSI 7100 Bioanalyzer. Measurements were conducted over a 24 hr
time period and normalized to cell number area under the curve, as previously
described (London˜o Gentile et al., 2013). Briefly, metabolite consumption was
defined as v = V(xmedium control  xfinal)/A, where v is metabolite consumption/
production, V is culture volume, x is metabolite concentration, and A is cell
number area under the curve. A was calculated as N(T)d/ln2(1  2T/d), where
N(T) is the final cell count, d is doubling time, and T is time of experiment.
Doubling timewas calculated as d = (T)[log(2)/log(Q2/Q1)], whereQ1 is starting
cell number and Q2 is final cell number, as determined by manual counting
using a hemocytometer.
Mass Spectrometry Analysis of Histones
For 12C study, LN229 cells in triplicate wells were incubated for 24 hr in 1mMor
10mM glucose. For 13C study, LN229 cells were first cultured in 1mM glucose
overnight. Triplicate wells of cells were then treated with 1 or 10 mM [U-13C]
glucose for 2 or 24 hr. Histones were acid extracted, as described in the Sup-
plemental Experimental Procedures. Total histones were subjected to chemi-
cal derivatization using propionic anhydride (Sigma-Aldrich) and digested with
sequencing-grade trypsin at a 10:1 substrate:enzyme ratio for 6 hr at 37C.
The digested peptides were treated with an additional round of propionylation
for the purpose of adding propionyl group to the newly generated N terminus.
Peptides were desalted using C18 extracted mini disk (Empore 3M) and dis-
solved in 0.1% formic acid. Approximately 1 mg of each sample was loaded
via an autosampler (EASY-nLC, Thermo Fisher Scientific) onto a homemade
75 mm reversed-phase analytical column packed with 15 cm C18-AQ resin
(3 mm particle sizes, 120 A˚ pore size) at a rate of 550 nl/min. Peptides were
chromatographically resolved on a 66 min 2%–98% solvent B gradient (sol-
vent A = 0.1% formic acid, solvent B = 100% acetonitrile) at a flow rate of
250 nl/min. The eluted peptides were electrosprayed through a PicoTip Emitter
(New Objective) and detected by LTQ Orbitrap Velos Mass Spectrometer
(Thermo Fisher Scientific). A resolution of 60,000 was used in the Orbitrap
for the full mass spectrometry (MS), followed by MS/MS spectra collected in
the ion trap.
After the MS data were generated, an in-house program was developed to
calculate the relative intensity of 13C-enriched acetyl groups. For example,
there are four acetyl groups in histone H4 residues 4–17 (K5/8/12/16), with a
2 Dalton mass shift between adjacent groups. Because the isotope patterns
of adjacent groups overlap, the intensity from the former group should be
subtracted. After calibration, the intensity of each group divided by the total
intensity is the relative intensity.
RNA Sequencing
LN229 cells were incubated for 24 hr in 1 mM or 10 mM glucose, or 1 mM
glucose + 5 mM sodium acetate. RNA was isolated using TRIzol reagent
and submitted to the Functional Genomics Core at the University of Pennsyl-
vania for library preparation and sequencing. Details of data analysis and
clustering may be found in the Supplemental Experimental Procedures.
LC-MS Metabolite Measurements
Acetyl-CoA and CoASH measurements were conducted as previously
described (Basu and Blair, 2012; Basu et al., 2011). Detailed protocol is
included in the Supplemental Experimental Procedures. For molar concentra-
tions, measurements were normalized to cell volume, as determined using a
Coulter Z2 Particle Counter, as previously described (Wellen et al., 2010). Pro-
tocol for citrate and glutamate analysis is also described in the Supplemental
Experimental Procedures.
Histone Acetylation in Isolated Nuclei Assay
Nuclei were isolated from approximately 9 3 106 adherent LN229 cells by us-
ing a cell lifter and cold nuclear isolation buffer (NIB) (15 mM Tris-HCL [pH 7.5],
60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 1 mM CaCl2, 250 mM sucrose, 0.1%CelNP-40). Nuclei were pelleted at 600 RCF (relative centrifugal force) for 5 min in
4C and followed by two washes using NIB buffer without NP-40. Nuclei were
suspended with indicated concentrations of acetyl-CoA and CoASH in 200 ml
NIB buffer without NP-40 for 1 hr at 37C. After incubation, nuclei were pelleted
at 600 RCF for 5 min and subjected to acid extraction (described in the Sup-
plemental Experimental Procedures).
Immunohistochemistry and Scoring of Murine Tissues
For histological evaluation, tissue samples were harvested as described (Gun-
ther et al., 2002; Rhim et al., 2012). Immunohistochemistry was performed on
paraffin-embedded sections. Tissue sections were dewaxed and rehydrated.
Antigen retrieval was performed by boiling samples in citrate buffer (pH 6) for
20 min (for AcH4, AcH3, and H3K4me) or in Tris-EDTA 10 mM buffer (pH 9) for
45 min (pAcly), and endogenous peroxidase was blunted by incubating sam-
ples with 3% H2O2 for 10 min. After incubation with the primary antibody,
slides were rinsed in PBS, and signals were developed using the Vectastain
Elite Kit and 3,30-diaminobenzidine as a substrate for the peroxidase chro-
mogenic reaction (Vector Laboratories). At least three animals/group were
evaluated. All animal studies were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee (IACUC).
Quantification of AcH4 positivity in acinar cells in Kras WT and KPCY
mice (n = 5/group) was performed in a semiautomated manner using ImageJ
software. For each animal, 5–10 images from different, nonoverlapping micro-
scopic fields were analyzed. Images containing malignant or premalignant
lesions were excluded from the analysis. Count of nuclei within each image
was calculated using ImageJ, while positive nuclei were scored by a blinded
evaluator. Ductal and islet cells were excluded by the evaluator.
Immunohistochemistry and Automated Scoring for Human Gliomas
Cases were obtained from the University of Pennsylvania following approval
from the institutional review board. All cases were deidentified prior to
analysis and contained in previously well-characterized tissue microarray
sections (Venneti et al., 2013a). The cohort consisted of a total of 56 glioma
samples (4 WHO grade II oligodendrogliomas, 5 grade III anaplastic oligo-
dendrogliomas, 6 grade II oligoastrocytomas, 4 grade I pilocytic astrocy-
tomas, 4 grade II diffuse astrocytomas, 9 grade III anaplastic astrocytomas,
14 grade IV glioblastomas, 2 grade I gangliogliomas, and 8 grade II ependy-
momas). A neuropathologist evaluated all cases. Immunohistochemical
studies and quantification were performed as previously described (Venneti
et al., 2013b). Details may be found in the Supplemental Experimental
Procedures.
Immunohistochemistry and Scoring of Human Prostate Tumors
Caseswere obtained from the University of Pennsylvania following institutional
review board approval. TMAs were assembled from primary tumors from 49
patients with either metastatic (n = 25) or localized (n = 24) disease. Sections
(5 mm) from formalin-fixed paraffin-embedded (FFPE) TMA tissue blocks
were prepared for immunohistochemical stain. Details of the staining and
scoring are provided in the Supplemental Experimental Procedures.
Statistical Analyses
Student’s two-tailed t tests were used for all analyses directly comparing two
data sets. For in vitro assay testing AcCoA and CoASH effects on histone acet-
ylation, repeated-measures one-way ANOVAwas used, with posttest for linear
trend. For correlations shown for human IHC, Pearson’s product-moment
correlation coefficient (Pearson’s r) and corresponding two-tailed significance
(p value) were determined.
ACCESSION NUMBERS
Data have been deposited in the GEO database under accession number
GSE57488.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
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